The Leptin Connection: Regulatory T Cells and Autoimmunity  by Hasenkrug, Kim J.
contamination of the HSP prepara-
tions. A potential resolution comes
from studies that compared and com-
bined purified HSP and lipopolysac-
charide; these studies revealed that
putatively ‘‘clean’’ HSPs induce re-
sponses but also enhance responses
to lipopolysaccharide (Warger et al.,
2006). Thus, the critical role that Yang
et al. revealed for gp96 in TLR function
represents a unique example of the
many roles that HSPs may play in
regulating immune responses.
The results from the study by Yang
et al. provide new insight into the role
of HSPs in the assembly of functional
TLRs, but how can this knowledge be
used in future studies? At this point,
therapeutic application seems remote.
gp96 is not TLR specific, serves as
a necessary chaperone for many pro-
teins, and is essential in embryogene-
sis. Therefore, it may be a problematic
target for therapy, although inhibition
of its function could theoretically be
used to decrease TLR expression in
diseases with excessive proinflamma-
tory TLR signaling. Perhaps the most
exciting application developed by this
study is the generation of cell-lineage-
specific TLR deficiency that can be
used in future studies for analyzing
the roles of TLRs on a specific cell
type. The authors used this to address
the specific contributions of macro-
phages, as opposed to dendritic cells
or other TLR-expressing cells, in
endotoxin shock and infection with
L. monocytogenes, but this approach
could also be applied in the study of
many other disease states. Many
pathogens that infect macrophages
also infect dendritic cells, and the bal-
ance of contributions of these cell
types to the generation of innate
immunity or effector T cell responses
remains undetermined in many infec-
tious diseases. In addition, a similar
strategy could be used for generating
mice with TLR deficiencies in other
cell lineages. For example, some T
cells express a subset of TLRs, but
the function of T cell-expressed TLRs
in immune responses or disease path-
ogenesis remains unclear, and a
mouse lacking gp96 and TLR expres-
sion in T cells might provide a way to
address such questions, as long as
gp96 does not have other essential
functions in this lineage. It should
be noted that TLRs often provide re-
dundant signaling to pathogens that
express agonists for multiple TLRs,
and many researchers desire some
sort of general TLR-deficient model
for their experiments. Within the con-
fines of a cell-lineage-specific knock-
out, gp96 deficiency may provide
such a general knockout of TLR func-
tion. In summary, Yang et al. provide
important insight into the role of gp96
in the generation of functional TLRs,
and their work provides exciting tools
and approaches for future studies of
TLR function and the contribution of
specific cell types in immune re-
sponses and immunopathology.
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Leptin is a cytokine-like hormone with proinflammatory properties linked to autoimmune diseases. In
this issue of Immunity, De Rosa et al. (2007) elucidate an important new role for leptin in the anergy
and hyporesponsiveness of regulatory T cells.Leptin, a hormone primarily known for
control of appetite and obesity, is also
a proinflammatory cytokine that plays
a potent role in the control of autoim-
mune diseases (Otero et al., 2006).This role is apparent in the autoimmu-
nity-resistance phenotypes of mice
deficient in either leptin (encoded by
the obesity [ob] gene) or its receptor,
ObR (encoded by the diabetes [db]Immunity 26gene). In humans, increases in leptin
amounts are associatedwith ulcerative
colitis (Tuzun et al., 2004) and the onset
of multiple sclerosis (Matarese et al.,
2005). Despite strong evidence for the, February 2007 ª2007 Elsevier Inc. 143
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cise mechanism of its activity has
been controversial, and both direct
(Lord et al., 1998) and indirect (Palmer
et al., 2006) mechanisms have been
described. Much of the difficulty has
lain in the highly pleiotropic activities
of leptin on both the neuroendocrine
and immune systems. In the immune
system alone, leptin can directly affect
the activity of numerous immune cell
types of both the innate and adaptive
systems. It can also produce a wide
range of indirect effects such as stimu-
lation of proinflammatory cytokines,
which themselves have pleiotropic
effects. Now a key piece of the puzzle
regarding leptin’s role in autoimmune
diseases has been put in place by De
Rosa et al. (2007) and directly links
leptin to regulatory T cell anergy and
hyporesponsiveness.
A critical protective role for
CD4+CD25+ regulatory T cells in nu-
merous autoimmune diseases is now
well established, on the basis of initial
findings from the Sakaguchi lab (Saka-
guchi et al., 2006). A clue that leptin
might be involved in the homeostasis
of regulatory Tcells came froma recent
study showing that increases in leptin
inmultiple sclerosis patients correlated
with reduced numbers of regulatory T
cells (Matarese et al., 2005). The cur-
rent paper presents strong evidence
that such reductions are likely a direct
consequence of leptin binding to re-
ceptors on the regulatory T cells. Reg-
ulatory T cells are normally anergic and
hyporesponsive toTcell receptor (TCR)
signaling, but De Rosa et al. (2007)
show that specific neutralization of lep-
tin combined with TCR signaling re-
versed anergy and hyporesponsive-
ness. Proliferation was dependent on
IL-2 but appeared to operate through
a distinct mechanism. Interestingly,
an important source of leptin was the
regulatory T cells themselves, which
both secreted leptin and expressed
leptin receptors. Thus, leptin canmedi-
ate a negative autocrine loop in regula-
tory T cells even in the absence of ex-
ogenous leptin (Figure 1). The reversal
of anergy by leptin neutralization was
associated with phosphorylation of
ERK1 and ERK2 kinase and rapid
degradation of the cell-cycle inhibitor
p27kip1. Importantly, regulatory T cells144 Immunity 26, February 2007 ª2007 EFigure 1. Opposite Effects of Leptin on Regulatory and Effector T Cells Promote
Inflammatory Responses
Circulating or locally produced leptin binds to CD4+CD25+ regulatory T cells and CD4+CD25
effector T cells via the leptin receptor. Binding upregulates both leptin and leptin-receptor
expression in both cell types. In regulatory T cells, leptin-receptor signaling leads to anergy and
hyporesponsiveness, whereas in effector T cells, it leads to Th1 polarization (increased IFN-g,
decreased IL-4) and secretion of proinflammatory cytokines (e.g., TNF-a) that further activate
leptin production and synergistically potentiate leptin function.that were expanded in the presence
of leptin antibody retained their immu-
nosuppressive phenotype for up to 8
days in culture.
In vivo results supported a role for
leptin-receptor signaling in impaired
regulatory T cell proliferation. Mice
with genetic deficiency of leptin had
higher percentages and absolute num-
bers of circulating regulatory T cells.
Furthermore, wild-type regulatory T
cells adoptively transferred into lep-
tin-deficient mice expanded substan-
tially more than those transferred into
wild-typemice. Thus, regulatory T cells
proliferated better in a leptin-poor envi-
ronment. Consistent with that conclu-
sion, treatment of wild-type mice with
leptin-neutralizing antibody produced
an expansion of regulatory T cells. In
contrast, administration of leptin re-
duced the numbers of regulatory
T cells in leptin-deficient mice to
amounts equivalent to those in wild-
typemice.Given theproven role of reg-
ulatory T cells in protection from auto-
immune diseases, it appears that at
least part of the resistance to autoim-
mune disease in leptin-deficient and
leptin-receptor-deficient mice may be
due to increased numbers of regula-
tory T cells. Interestingly, De Rosa
et al. (2007) also showed that although
leptin had a negative impact on regula-
tory T cell proliferation, it had the oppo-
site effect on conventional CD4+ T cells
(Figure 1). In contrast to results from
regulatory T cells, in vitro expansion
of conventional CD4+CD25 T cells by
stimulation with CD3 and CD28 anti-lsevier Inc.bodies was markedly less effective on
cells lacking the leptin receptor than
on wild-type cells. Furthermore, neu-
tralizing leptin reduced the proliferation
of conventional CD4+CD25 T cells in
vitro. These effects were not peculiar
to anti-CD3 and anti-CD28 stimulation
because similar findings were made
when stimulation was done with a pan-
creatic autoantigen in the nonobese-
diabetic-mouse model coupled with a
leptin-receptor mutation. Thus, the in-
creased resistance to autoimmune
disease and susceptibility to infection
in leptin-deficient and leptin-receptor-
deficient mice is likely a combined
effect fromenhancementof the immune-
system regulatory armwith a concomi-
tant impairment of the effector arm.
It is intriguing that a hormone that is
primarily produced by adipocytes and
controls food intake and energy ex-
penditure is so intimately involved in
immunoregulation. Numerous associ-
ations between nutrition and the im-
mune system have been made, some
already linked to leptin. For example,
acute starvation in mouse experimen-
tal autoimmune encephalitis results in
reduced leptin amounts and delayed
onset of disease (Sanna et al., 2003).
In humans, there is an association
between obesity, high leptin amounts,
and inflammatory conditions such
as rheumatoid arthritis. Furthermore,
food deprivation, which reduces leptin
amounts, can sometimes ameliorate
symptoms of inflammatory diseases.
In addition to effects from leptin, im-
munosuppression due to low nutrition
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Previewsmay be related to the fact that lympho-
cytes are very sensitive to nutritional
status because they do not store gly-
cogen and rely on the import of extra-
cellular glucose for their energy supply
(La Cava and Matarese, 2004). From
an evolutionary perspective, it may
make survival sense to dampen im-
mune responsiveness during periods
of starvation in order to divert more
energy to food gathering.
The new data provide a possible
strategy for expanding regulatory T
cells in vitro that retain suppressive
activity. It will be of great interest to
determine whether such cells can be
used therapeutically in the treatment
of autoimmune diseases. The results
also open up new ways of thinking
about therapies targeting leptin in vivo
for the treatment of inflammatory
and autoimmune diseases. However,
in addition to the effects previously
mentioned, leptin also influences he-
matopoiesis, angiogenesis, bone and
lipid metabolism, insulin secretion,
and the reproductive system. Conse-
quently, in vivo treatments targeting
such a broad-acting molecule present
a high risk of unexpected and undesir-HIV’s Vagina Tra
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Details of how HIV-1 is transmitte
Hladik et al. (2007) describe an o
thelial T cells and Langerhans ce
Travelogue: An (illustrated) lec-
ture about places and experi-
ences encountered in the
course of travel; hence a film,
broadcast, book, etc., about
travel; a travel documentary.
(Oxford English Dictionary
online: http://www.oed.com/)
The female genital tract is the primary
route for heterosexual transmission ofable side effects, and considerable
caution and more research are war-
ranted. That said, it will be interesting,
for example, to determinewhether lep-
tin might serve as a natural adjuvant
in vaccinations. Used in a localized
rather than systemic manner, leptin
might simultaneously stimulate T
helper 1 (Th1) responses while down-
modulating regulatory T cells to pro-
duce uniquely potent T cell priming
without producing substantial side ef-
fects. It might also be possible in the
future to expand or contract antigen-
specific subsets of regulatory T cells
through the use of bivalent leptin-
receptor agonists or antagonists. An-
other possible strategy to avoid side
effects might be to use siRNA or other
inhibitors to target downstream sig-
nal-transduction pathways in distinct
cell types. Thus, the new findings on
regulatory T cell and leptin biology
reported by De Rosa et al. (2007)
expand the context for discerning
how regulatory T cell homeostasis
might be perturbed in pathogenic re-
sponses and provide insights into
how we might modulate responses
therapeutically.velogue
1,*
ll Institute of Biomolecular Medicine, New Yo
.edu
d across mucosal barriers remain s
rgan culture system for imaging H
lls early after infection.
the human immunodeficiency virus
(HIV1, referred to in the text as HIV).
On the basis of studies with macaques
exposed to simian immunodeficiency
virus (SIV), it is thought that during
male-to-female transmission, virus in
semen, either cell-free or cell-associ-
ated, penetrates the stratified squa-
mous epithelium of the vagina or the
columnar epithelium of the endocervix
to infect cells within or below the epi-
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IV-1 interaction with vaginal epi-
thelium (reviewed in Pope and Haase,
[2003]). This is followed by dissemina-
tion of the virus to lymphoid organs,
particularly gut-associated lymphoid
tissues (GALT), within the first few
days after infection (Li et al., 2005).
Despite intensive efforts to uncover
mechanisms by which HIV traverses
the mucosal barriers and establishes
infection, our understanding of this
process remains limited. It is unclear
, February 2007 ª2007 Elsevier Inc. 145
